Health Care/Hospital
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it plans to change the ratio of its American d...
2024-07-12 04:00
3874
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation
SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- Medit, a global leader in dental 3D scanners and digital dentistry solutions, has appointedHan Ryu as its new CEO. Ryu brings with him over three decades of senior management experience in global medical device and healthcare companies, including ...
2024-07-11 21:00
2508
First Patient Dosed in Phase I Clinical Trial of YOLT-201
SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo g...
2024-07-11 20:11
1806
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
SHANGHAI, July 11, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tech...
2024-07-11 20:00
1891
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric...
2024-07-11 14:21
2061
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...
2024-07-11 14:07
1990
Official Swiss delegation experiences new frontiers in art tech at HKBU
HONG KONG, July 11, 2024 /PRNewswire/ -- A senior Swiss delegation led by Mr Guy Parmelin, Swiss Federal Councillor and Head of the Federal Department of Economic Affairs, Education and Research, visited Hong KongBaptist University (HKBU) on 5 July. The delegation was able to partake in the premi...
2024-07-11 13:34
1599
Kangsters Unveils Revolutionary Treadmills at Rollettes Experience 2024: Celebrating Innovation and Empowerment
LOS ANGELES, July 10, 2024 /PRNewswire/ -- Kangsters, the pioneering South Korean adaptive tech startup, proudly announces its participation in the Rollettes Experience 2024. This renowned event, now celebrating its 11th anniversary, will be held fromJuly 11-14 at the Sheraton Hotel in Los Angele...
2024-07-11 00:00
2190
Snorles GenioFlex: The Innovative Daytime Solution for Snoring Management Now Launched on Indiegogo
HONG KONG, July 10, 2024 /PRNewswire/ -- Snorles, a leading innovator in sleep technology, is excited to announce the launch of its latest product, GenioFlex. Snorles created to address snoring issues and promote overall health and well-being, GenioFlex offers a fresh approach to managing snoring...
2024-07-10 20:02
1747
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...
2024-07-10 13:30
3462
KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells
Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...
2024-07-09 23:00
2095
Bestqool Pro Series Redefines the Standard of Red Light Therapy Devices: Cutting-Edge Technology Undergone the Third-party Laboratory Diagnostic Testing
NEW YORK, July 9, 2024 /PRNewswire/ -- Bestqool, as one of the industry's top makers of innovative red light therapy devices for over six years, in recent months proactively sent their Pro Series devices to LightLab International Allentown LLC, a reputable third-party laboratory in the US. Bestqo...
2024-07-09 21:00
2253
Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring (CGM) solutions and automotive-grade Bluetooth LE SoC at the electronicaChina 2024. Demonstrating a dedication to innovation in sensing and wireless technology, Goodix showcased its la...
2024-07-08 22:00
2254
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced
that Enabling Technologies Consortium (ETC) has awarded a two-year contract to
J-STAR to collaborate on "Co-processing Platform Technology."
2024-07-08 22:00
1544
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
* Tergase® poised to capture a fair share of the global hyaluronidase market.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-08 21:00
2085
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...
2024-07-08 17:23
1483
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...
2024-07-08 17:00
1523
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
2024-07-08 16:28
1509
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical tri...
2024-07-08 13:41
1672
Hainan Free Trade Port deepens cooperation with Switzerland
HAIKOU, China, July 7, 2024 /PRNewswire/ -- A report from Hainan International
Media Center (HIMC):
2024-07-07 22:36
2789
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10968
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
8352
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6821
